NCM
EGRX

Nantahala Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Nantahala Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,356,536
Closed -$8.79M – 155
2024
Q3 		$8.79M Buy
2,356,536
+394,466
+20% +$1.88M 0.44% 44
2024
Q2 		$11M Buy
1,962,070
+703,308
+56% +$3.06M 0.64% 34
2024
Q1 		$6.6M Buy
+1,258,762
New +$6.91M 0.38% 52

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $984M AUM 72.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $508M AUM 24.82% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Nantahala Capital Management's EGRX Position: Q4 2024 in Review

Nantahala Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 2,356,536 shares — an estimated $8.79M sold.

Nantahala Capital Management first reported a position in EGRX in Q1 2024 and held it in 3 quarters. The position peaked at $11M in Q2 2024. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Nantahala Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Nantahala Capital Management sold 2,356,536 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $8.79M.
  • Nantahala Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2024 and held it in 3 quarters.
  • Nantahala Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $11M in Q2 2024.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Nantahala Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.